Annual FCF
$1.05 B
+$275.26 M+35.57%
31 December 2023
Summary:
Jazz Pharmaceuticals annual free cash flow is currently $1.05 billion, with the most recent change of +$275.26 million (+35.57%) on 31 December 2023. During the last 3 years, it has risen by +$528.65 million (+101.59%). JAZZ annual FCF is now at all-time high.JAZZ Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
$387.96 M
+$63.70 M+19.64%
30 September 2024
Summary:
Jazz Pharmaceuticals quarterly free cash flow is currently $387.96 million, with the most recent change of +$63.70 million (+19.64%) on 30 September 2024. Over the past year, it has increased by +$85.06 million (+28.08%). JAZZ quarterly FCF is now -8.26% below its all-time high of $422.89 million, reached on 30 September 2022.JAZZ Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
$1.10 B
+$85.06 M+8.37%
30 September 2024
Summary:
Jazz Pharmaceuticals TTM free cash flow is currently $1.10 billion, with the most recent change of +$85.06 million (+8.37%) on 30 September 2024. Over the past year, it has increased by +$234.38 million (+27.02%). JAZZ TTM FCF is now at all-time high.JAZZ TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
JAZZ Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +35.6% | +28.1% | +27.0% |
| 3 y3 years | +101.6% | +56.5% | +54.9% |
| 5 y5 years | +57.2% | +44.8% | +51.7% |
JAZZ Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +101.6% | -8.3% | +1014.9% | at high | +77.2% |
| 5 y | 5 years | at high | +101.6% | -8.3% | +1014.9% | at high | +142.2% |
| alltime | all time | at high | +759.9% | -8.3% | +748.7% | at high | +779.2% |
Jazz Pharmaceuticals Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $387.96 M(+19.6%) | $1.10 B(+8.4%) |
| June 2024 | - | $324.26 M(+29.5%) | $1.02 B(+3.4%) |
| Mar 2024 | - | $250.32 M(+79.8%) | $983.48 M(-6.2%) |
| Dec 2023 | $1.05 B(+35.6%) | $139.24 M(-54.0%) | $1.05 B(+20.9%) |
| Sept 2023 | - | $302.90 M(+4.1%) | $867.40 M(-12.2%) |
| June 2023 | - | $291.03 M(-7.9%) | $987.40 M(+7.6%) |
| Mar 2023 | - | $315.89 M(-844.9%) | $917.98 M(+18.6%) |
| Dec 2022 | $773.78 M(+5.6%) | -$42.41 M(-110.0%) | $773.78 M(-21.4%) |
| Sept 2022 | - | $422.89 M(+90.8%) | $983.98 M(+21.6%) |
| June 2022 | - | $221.61 M(+29.1%) | $808.93 M(+30.1%) |
| Mar 2022 | - | $171.69 M(+2.3%) | $621.83 M(-15.2%) |
| Dec 2021 | $732.98 M(+40.9%) | $167.79 M(-32.3%) | $732.98 M(+3.0%) |
| Sept 2021 | - | $247.84 M(+618.0%) | $711.34 M(+0.5%) |
| June 2021 | - | $34.52 M(-87.8%) | $708.02 M(-5.6%) |
| Mar 2021 | - | $282.83 M(+93.5%) | $750.33 M(+44.2%) |
| Dec 2020 | $520.39 M(-12.4%) | $146.16 M(-40.2%) | $520.39 M(+14.4%) |
| Sept 2020 | - | $244.52 M(+218.3%) | $454.90 M(-4.9%) |
| June 2020 | - | $76.83 M(+45.3%) | $478.30 M(-6.0%) |
| Mar 2020 | - | $52.89 M(-34.4%) | $508.65 M(-14.4%) |
| Dec 2019 | $594.07 M(-11.0%) | $80.66 M(-69.9%) | $594.07 M(-18.2%) |
| Sept 2019 | - | $267.92 M(+150.0%) | $726.35 M(+7.5%) |
| June 2019 | - | $107.18 M(-22.5%) | $675.97 M(+4.7%) |
| Mar 2019 | - | $138.31 M(-35.1%) | $645.53 M(-3.3%) |
| Dec 2018 | $667.43 M(+15.2%) | $212.95 M(-2.1%) | $667.43 M(+3.9%) |
| Sept 2018 | - | $217.54 M(+183.5%) | $642.17 M(+21.1%) |
| June 2018 | - | $76.74 M(-52.1%) | $530.18 M(-8.3%) |
| Mar 2018 | - | $160.21 M(-14.6%) | $578.38 M(-0.1%) |
| Dec 2017 | $579.14 M(+41.6%) | $187.68 M(+77.8%) | $579.14 M(+1.4%) |
| Sept 2017 | - | $105.55 M(-15.5%) | $570.87 M(-1.7%) |
| June 2017 | - | $124.94 M(-22.4%) | $580.97 M(+35.3%) |
| Mar 2017 | - | $160.97 M(-10.3%) | $429.49 M(+5.0%) |
| Dec 2016 | $408.95 M(-17.5%) | $179.42 M(+55.1%) | $408.95 M(+18.2%) |
| Sept 2016 | - | $115.65 M(-535.7%) | $345.91 M(-13.6%) |
| June 2016 | - | -$26.54 M(-118.9%) | $400.18 M(-27.8%) |
| Mar 2016 | - | $140.43 M(+20.7%) | $554.27 M(+11.8%) |
| Dec 2015 | $495.99 M | $116.37 M(-31.5%) | $495.99 M(-0.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2015 | - | $169.92 M(+33.2%) | $499.70 M(+32.8%) |
| June 2015 | - | $127.55 M(+55.3%) | $376.34 M(+21.2%) |
| Mar 2015 | - | $82.14 M(-31.6%) | $310.58 M(+84.2%) |
| Dec 2014 | $168.63 M(-38.0%) | $120.09 M(+157.9%) | $168.63 M(+35.5%) |
| Sept 2014 | - | $46.56 M(-24.7%) | $124.48 M(-39.4%) |
| June 2014 | - | $61.79 M(-203.3%) | $205.56 M(+38.0%) |
| Mar 2014 | - | -$59.80 M(-178.8%) | $148.92 M(-45.3%) |
| Dec 2013 | $272.17 M(+19.8%) | $75.93 M(-40.5%) | $272.17 M(-7.4%) |
| Sept 2013 | - | $127.64 M(+2377.4%) | $293.85 M(+42.2%) |
| June 2013 | - | $5.15 M(-91.9%) | $206.60 M(-22.9%) |
| Mar 2013 | - | $63.45 M(-35.0%) | $267.96 M(+17.9%) |
| Dec 2012 | $227.28 M(+55.9%) | $97.61 M(+141.6%) | $227.28 M(+32.6%) |
| Sept 2012 | - | $40.39 M(-39.3%) | $171.44 M(-2.4%) |
| June 2012 | - | $66.51 M(+192.2%) | $175.61 M(+20.8%) |
| Mar 2012 | - | $22.76 M(-45.5%) | $145.32 M(-0.3%) |
| Dec 2011 | $145.82 M(+169.3%) | $41.78 M(-6.3%) | $145.82 M(+16.0%) |
| Sept 2011 | - | $44.57 M(+23.1%) | $125.72 M(+27.9%) |
| June 2011 | - | $36.22 M(+55.7%) | $98.32 M(+36.6%) |
| Mar 2011 | - | $23.26 M(+7.3%) | $71.98 M(+33.0%) |
| Dec 2010 | $54.14 M(-346.9%) | $21.68 M(+26.3%) | $54.14 M(+73.4%) |
| Sept 2010 | - | $17.17 M(+73.9%) | $31.23 M(+5255.9%) |
| June 2010 | - | $9.88 M(+82.4%) | $583.00 K(-105.6%) |
| Mar 2010 | - | $5.41 M(-538.7%) | -$10.36 M(-52.8%) |
| Dec 2009 | -$21.93 M(-86.2%) | -$1.23 M(-90.8%) | -$21.93 M(-52.9%) |
| Sept 2009 | - | -$13.47 M(+1159.1%) | -$46.56 M(-24.7%) |
| June 2009 | - | -$1.07 M(-82.6%) | -$61.83 M(-46.9%) |
| Mar 2009 | - | -$6.16 M(-76.2%) | -$116.50 M(-26.7%) |
| Dec 2008 | -$158.97 M(+88.7%) | -$25.86 M(-10.0%) | -$158.97 M(-2.0%) |
| Sept 2008 | - | -$28.75 M(-48.4%) | -$162.22 M(+8.6%) |
| June 2008 | - | -$55.74 M(+14.6%) | -$149.43 M(+33.8%) |
| Mar 2008 | - | -$48.63 M(+67.1%) | -$111.68 M(+32.6%) |
| Dec 2007 | -$84.24 M(+42.7%) | -$29.10 M(+82.3%) | -$84.24 M(+52.8%) |
| Sept 2007 | - | -$15.96 M(-11.2%) | -$55.14 M(+40.8%) |
| June 2007 | - | -$17.99 M(-15.1%) | -$39.17 M(+84.9%) |
| Mar 2007 | - | -$21.18 M | -$21.18 M |
| Dec 2006 | -$59.03 M(+10.2%) | - | - |
| Dec 2005 | -$53.58 M | - | - |
FAQ
- What is Jazz Pharmaceuticals annual free cash flow?
- What is the all time high annual FCF for Jazz Pharmaceuticals?
- What is Jazz Pharmaceuticals annual FCF year-on-year change?
- What is Jazz Pharmaceuticals quarterly free cash flow?
- What is the all time high quarterly FCF for Jazz Pharmaceuticals?
- What is Jazz Pharmaceuticals quarterly FCF year-on-year change?
- What is Jazz Pharmaceuticals TTM free cash flow?
- What is the all time high TTM FCF for Jazz Pharmaceuticals?
- What is Jazz Pharmaceuticals TTM FCF year-on-year change?
What is Jazz Pharmaceuticals annual free cash flow?
The current annual FCF of JAZZ is $1.05 B
What is the all time high annual FCF for Jazz Pharmaceuticals?
Jazz Pharmaceuticals all-time high annual free cash flow is $1.05 B
What is Jazz Pharmaceuticals annual FCF year-on-year change?
Over the past year, JAZZ annual free cash flow has changed by +$275.26 M (+35.57%)
What is Jazz Pharmaceuticals quarterly free cash flow?
The current quarterly FCF of JAZZ is $387.96 M
What is the all time high quarterly FCF for Jazz Pharmaceuticals?
Jazz Pharmaceuticals all-time high quarterly free cash flow is $422.89 M
What is Jazz Pharmaceuticals quarterly FCF year-on-year change?
Over the past year, JAZZ quarterly free cash flow has changed by +$85.06 M (+28.08%)
What is Jazz Pharmaceuticals TTM free cash flow?
The current TTM FCF of JAZZ is $1.10 B
What is the all time high TTM FCF for Jazz Pharmaceuticals?
Jazz Pharmaceuticals all-time high TTM free cash flow is $1.10 B
What is Jazz Pharmaceuticals TTM FCF year-on-year change?
Over the past year, JAZZ TTM free cash flow has changed by +$234.38 M (+27.02%)